Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-02-03 Aldosterone antagonists
Links
Enoxaparin for Treatment of Venous Thromboembolism **FOR USE IN THE BLACKPOOL REGION ONLY** - Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY* - LSC Hypertension in Adults: Diagnosis and Management
- LSC Patient Pathway for Commencing Inclisiran
- LSC Statin Intolerance Pathway
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- MHRA Drug Safety Update Dec 2016: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
- MHRA Drug Safety Update Feb 2016: https://www.gov.uk/drug-safety-update/spironolactone-and-renin-angiotensin-system-drugs-in-heart-failure-risk-of-potentially-fatal-hyperkalaemia
- MHRA Drug Safety Update Feb 2016: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article
- MHRA Drug Safety Update: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
- MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
- MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
- MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article
- MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG185: Acute Coronary Syndromes
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG196: Atrial fibrillation: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA877 Finerenone for treating chronic kidney disease in type 2 diabetes
- NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes
- Policy and procedure for prophylaxis against, and treatment of, VTE in adult patients **FOR USE IN THE CENTRAL LANCS REGION ONLY**
- Prevention of VTE in Medical Surgical Patients (16 years +) and those requiring lower limb plaster casts/immobilisations **FOR USE IN THE BLACKPOOL REGION ONLY**
- Renal: Enhanced Supportive Kidney Care Guideline